ACACB
Basic information
Region (hg38): 12:109116587-109268226
Links
Phenotypes
GenCC
Source:
- isolated cleft palate (Limited), mode of inheritance: Unknown
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the ACACB gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 35 | 10 | 46 | |||
missense | 162 | 20 | 188 | |||
nonsense | 0 | |||||
start loss | 0 | |||||
frameshift | 0 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 12 | 4 | 16 | |||
non coding | 14 | |||||
Total | 0 | 0 | 163 | 62 | 23 |
Variants in ACACB
This is a list of pathogenic ClinVar variants found in the ACACB region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
12-109139409-G-A | not specified | Likely benign (Nov 05, 2021) | ||
12-109139424-C-T | ACACB-related disorder | Benign (Dec 31, 2019) | ||
12-109139509-G-A | not specified | Uncertain significance (Nov 08, 2022) | ||
12-109139533-C-T | not specified • ACACB-related disorder | Likely benign (Jan 12, 2024) | ||
12-109139534-G-A | ACACB-related disorder | Likely benign (Aug 14, 2024) | ||
12-109139539-A-G | ACACB-related disorder | Conflicting classifications of pathogenicity (Oct 25, 2022) | ||
12-109139545-C-A | not specified | Uncertain significance (Apr 07, 2022) | ||
12-109139578-C-T | not specified | Likely benign (Aug 16, 2021) | ||
12-109139631-C-T | not specified | Uncertain significance (Dec 16, 2023) | ||
12-109139665-G-A | not specified | Likely benign (Apr 14, 2022) | ||
12-109139671-G-T | not specified | Uncertain significance (Nov 15, 2023) | ||
12-109139686-C-T | not specified | Uncertain significance (Jun 10, 2022) | ||
12-109139711-C-A | Likely benign (Dec 14, 2023) | |||
12-109139727-G-A | not specified | Uncertain significance (Apr 09, 2024) | ||
12-109139760-G-A | not specified | Uncertain significance (Mar 01, 2023) | ||
12-109139783-G-C | not specified | Uncertain significance (Jun 22, 2023) | ||
12-109139794-C-G | not specified | Uncertain significance (May 14, 2024) | ||
12-109139896-A-G | not specified | Uncertain significance (Jul 05, 2023) | ||
12-109139937-G-C | not specified | Uncertain significance (Feb 12, 2024) | ||
12-109139959-G-A | not specified | Conflicting classifications of pathogenicity (May 01, 2024) | ||
12-109139971-G-A | ACACB-related disorder | Likely benign (Feb 07, 2022) | ||
12-109139977-G-A | not specified | Uncertain significance (Aug 04, 2023) | ||
12-109140042-C-T | not specified | Uncertain significance (Oct 06, 2023) | ||
12-109140043-G-A | not specified | Uncertain significance (Jun 05, 2023) | ||
12-109140045-G-A | not specified | Likely benign (Jun 03, 2024) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
ACACB | protein_coding | protein_coding | ENST00000338432 | 52 | 151632 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
7.65e-47 | 0.191 | 125336 | 1 | 411 | 125748 | 0.00164 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 1.57 | 1347 | 1.52e+3 | 0.887 | 0.0000978 | 16104 |
Missense in Polyphen | 505 | 579.9 | 0.87084 | 6015 | ||
Synonymous | -0.142 | 628 | 623 | 1.01 | 0.0000437 | 4856 |
Loss of Function | 2.93 | 92 | 128 | 0.720 | 0.00000682 | 1393 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.00341 | 0.00334 |
Ashkenazi Jewish | 0.00418 | 0.00418 |
East Asian | 0.00246 | 0.00245 |
Finnish | 0.000370 | 0.000370 |
European (Non-Finnish) | 0.00127 | 0.00126 |
Middle Eastern | 0.00246 | 0.00245 |
South Asian | 0.00276 | 0.00268 |
Other | 0.00131 | 0.00130 |
dbNSFP
Source:
- Function
- FUNCTION: Catalyzes the ATP-dependent carboxylation of acetyl-CoA to malonyl-CoA. Carries out three functions: biotin carboxyl carrier protein, biotin carboxylase and carboxyltransferase. Involved in inhibition of fatty acid and glucose oxidation and enhancement of fat storage (By similarity). May play a role in regulation of mitochondrial fatty acid oxidation through malonyl- CoA-dependent inhibition of carnitine palmitoyltransferase 1 (By similarity). {ECO:0000250|UniProtKB:E9Q4Z2, ECO:0000269|PubMed:20952656}.;
- Pathway
- Pyruvate metabolism - Homo sapiens (human);Adipocytokine signaling pathway - Homo sapiens (human);Insulin resistance - Homo sapiens (human);Propanoate metabolism - Homo sapiens (human);AMPK signaling pathway - Homo sapiens (human);Glucagon signaling pathway - Homo sapiens (human);Fatty acid biosynthesis - Homo sapiens (human);Insulin signaling pathway - Homo sapiens (human);Metformin Pathway, Pharmacodynamic;AMP-activated Protein Kinase (AMPK) Signaling;Leptin signaling pathway;Activation of gene expression by SREBF (SREBP);Brain-Derived Neurotrophic Factor (BDNF) signaling pathway;JAK-STAT;Fatty Acid Biosynthesis;VEGFA-VEGFR2 Signaling Pathway;Liver steatosis AOP;Pathways in clear cell renal cell carcinoma;Hereditary Leiomyomatosis and Renal Cell Carcinoma Pathway;Biotin transport and metabolism;Metabolism of lipids;Regulation of cholesterol biosynthesis by SREBP (SREBF);Metabolism;Metabolism of water-soluble vitamins and cofactors;Metabolism of steroids;Metabolism of vitamins and cofactors;fatty acid biosynthesis initiation;biotin-carboxyl carrier protein assembly;Pyruvate metabolism;Leptin;Activation of gene expression by SREBF (SREBP)
(Consensus)
Recessive Scores
- pRec
- 0.412
Intolerance Scores
- loftool
- 0.0976
- rvis_EVS
- -1.97
- rvis_percentile_EVS
- 1.78
Haploinsufficiency Scores
- pHI
- 0.164
- hipred
- Y
- hipred_score
- 0.526
- ghis
- 0.566
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- gene_indispensability_pred
- N
- gene_indispensability_score
- 0.422
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | High | Medium | High |
Cancer | High | Medium | High |
Mouse Genome Informatics
- Gene name
- Acacb
- Phenotype
- muscle phenotype; cellular phenotype; homeostasis/metabolism phenotype; adipose tissue phenotype (the observable morphological and physiological characteristics of mammalian fat tissue that are manifested through development and lifespan); normal phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); growth/size/body region phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan);
Gene ontology
- Biological process
- acetyl-CoA metabolic process;fatty acid biosynthetic process;carnitine shuttle;negative regulation of gene expression;positive regulation of lipid storage;regulation of glucose metabolic process;response to organic cyclic compound;positive regulation of cellular metabolic process;response to nutrient levels;negative regulation of fatty acid beta-oxidation;response to drug;negative regulation of catalytic activity;regulation of cholesterol biosynthetic process;protein homotetramerization;positive regulation of heart growth;energy homeostasis;malonyl-CoA biosynthetic process
- Cellular component
- nucleus;mitochondrion;mitochondrial outer membrane;cytosol;endomembrane system
- Molecular function
- acetyl-CoA carboxylase activity;biotin carboxylase activity;protein binding;ATP binding;biotin binding;identical protein binding;metal ion binding